Main content

Cardiomyocyte-derived Erythropoietin: A Novel Player in Cardiac Regulation

Show simple item record

dc.contributor.advisor Simpson, Jeremy Alshamali, Razan 2020-01-07T17:02:24Z 2019-12 2019-10-25 2020-01-07
dc.description.abstract Recently, EPO emerged as a pleiotropic hormone with roles beyond hematopoiesis. While the kidney is considered the primary source of EPO, expression also occurs in other organs. Albeit, the physiological significance of these extra-renal sources is unknown. EPO is cardioprotective and increases myocardial contractility, in animal models. However, these studies rely on supraphysiological doses of rhEPO. Thus, the aim of this thesis was to identify an endogenous cardiac source of EPO and investigate its role in the heart. We hypothesized that the heart produces EPO and acts as an inotropic and a cytoprotective agent. A Cardiomyocyte-specific deletion of EPO (EPOfl/fl-CM) resulted in an increase in left ventricular EPO expression. This increase in cardiac-derived EPO did not translate to an increase in hematocrit levels. EPOfl/fl-CM mice exhibited an increase in inotropy and improved cardiac recovery post I/R. This thesis shows the heart as a non-renal source of EPO, regulating cardiac function. en_US
dc.language.iso en en_US
dc.subject Cardiac, disease, cytoprotection, regulation en_US
dc.subject Erythropoietin en_US
dc.subject Heart en_US
dc.subject cardiac disease en_US
dc.title Cardiomyocyte-derived Erythropoietin: A Novel Player in Cardiac Regulation en_US
dc.type Thesis en_US Human Health and Nutritional Sciences en_US Master of Science en_US Department of Human Health and Nutritional Sciences en_US
dc.description.embargo 2020-12
dc.rights.license All items in the Atrium are protected by copyright with all rights reserved unless otherwise indicated.

Files in this item

Files Size Format View
Alshamali_Razan_202001_Msc.pdf 1.902Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record